KnowBreastCancer StopBreastCancer Learn the Facts. Know the Evidence. Become an Advocate. Brought to you by NBCC

Month: July 2010

NBCC responds to ODAC vote on Avastin®

NBCC made the case in 2008 that accelerated approval for bevacizumab (Avastin®) was lowering the bar on drug approval. There was no evidence the drug extended the lives of breast cancer patients, and some evidence it increased the risk of harm. The FDA granted accelerated approval on the basis of a clinical trial showing an […]